Flavonoids in adipose tissue inflammation and atherosclerosis: one arrow, two targets.

Clinical Science (London, England : 1979) Pub Date : 2020-06-26 DOI:10.1042/CS20200356

Manal Muin Fardoun, Dina Maaliki, Nabil Halabi, Rabah Iratni, Alessandra Bitto, Elias Baydoun, Ali H Eid

{"title":"Flavonoids in adipose tissue inflammation and atherosclerosis: one arrow, two targets.","authors":"Manal Muin Fardoun, Dina Maaliki, Nabil Halabi, Rabah Iratni, Alessandra Bitto, Elias Baydoun, Ali H Eid","doi":"10.1042/CS20200356","DOIUrl":null,"url":null,"abstract":"<p><p>Flavonoids are polyphenolic compounds naturally occurring in fruits and vegetables, in addition to beverages such as tea and coffee. Flavonoids are emerging as potent therapeutic agents for cardiovascular as well as metabolic diseases. Several studies corroborated an inverse relationship between flavonoid consumption and cardiovascular disease (CVD) or adipose tissue inflammation (ATI). Flavonoids exert their anti-atherogenic effects by increasing nitric oxide (NO), reducing reactive oxygen species (ROS), and decreasing pro-inflammatory cytokines. In addition, flavonoids alleviate ATI by decreasing triglyceride and cholesterol levels, as well as by attenuating inflammatory mediators. Furthermore, flavonoids inhibit synthesis of fatty acids and promote their oxidation. In this review, we discuss the effect of the main classes of flavonoids, namely flavones, flavonols, flavanols, flavanones, anthocyanins, and isoflavones, on atherosclerosis and ATI. In addition, we dissect the underlying molecular and cellular mechanisms of action for these flavonoids. We conclude by supporting the potential benefit for flavonoids in the management or treatment of CVD; yet, we call for more robust clinical studies for safety and pharmacokinetic values.</p>","PeriodicalId":519494,"journal":{"name":"Clinical Science (London, England : 1979)","volume":" ","pages":"1403-1432"},"PeriodicalIF":0.0000,"publicationDate":"2020-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"27","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Science (London, England : 1979)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1042/CS20200356","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 27

Abstract

Flavonoids are polyphenolic compounds naturally occurring in fruits and vegetables, in addition to beverages such as tea and coffee. Flavonoids are emerging as potent therapeutic agents for cardiovascular as well as metabolic diseases. Several studies corroborated an inverse relationship between flavonoid consumption and cardiovascular disease (CVD) or adipose tissue inflammation (ATI). Flavonoids exert their anti-atherogenic effects by increasing nitric oxide (NO), reducing reactive oxygen species (ROS), and decreasing pro-inflammatory cytokines. In addition, flavonoids alleviate ATI by decreasing triglyceride and cholesterol levels, as well as by attenuating inflammatory mediators. Furthermore, flavonoids inhibit synthesis of fatty acids and promote their oxidation. In this review, we discuss the effect of the main classes of flavonoids, namely flavones, flavonols, flavanols, flavanones, anthocyanins, and isoflavones, on atherosclerosis and ATI. In addition, we dissect the underlying molecular and cellular mechanisms of action for these flavonoids. We conclude by supporting the potential benefit for flavonoids in the management or treatment of CVD; yet, we call for more robust clinical studies for safety and pharmacokinetic values.

查看原文本刊更多论文

脂肪组织炎症和动脉粥样硬化中的黄酮类化合物:一箭两靶。

类黄酮是一种多酚类化合物，天然存在于水果和蔬菜以及茶和咖啡等饮料中。黄酮类化合物正在成为心血管疾病和代谢疾病的有效治疗药物。一些研究证实了类黄酮摄入与心血管疾病(CVD)或脂肪组织炎症(ATI)之间的负相关关系。黄酮类化合物通过增加一氧化氮(NO)、减少活性氧(ROS)和降低促炎细胞因子发挥其抗动脉粥样硬化作用。此外，黄酮类化合物通过降低甘油三酯和胆固醇水平以及减轻炎症介质来减轻ATI。此外，黄酮类化合物还能抑制脂肪酸的合成，促进脂肪酸的氧化。本文综述了黄酮、黄醇、黄烷醇、黄烷酮、花青素和异黄酮等主要类黄酮在动脉粥样硬化和ATI中的作用。此外，我们剖析了这些类黄酮的潜在分子和细胞作用机制。我们的结论是支持类黄酮在心血管疾病管理或治疗中的潜在益处;然而，我们呼吁对安全性和药代动力学价值进行更强有力的临床研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Science (London, England : 1979)

自引率

0.00%

发文量